← All companies
Generate ideas →
UIUC
UIUC
Origin
ActiveAI and Data for Cancer Therapeutics
Winter 2026Founded 20254 peopleSan Francisco, CA, USA
AI insightcan contain mistakes
Cancer Drug Discovery DataTransactionalPharma companies and AI labsLow competition
Moat
Patient-derived, single-cell datasets with drug-effect screening are unique and difficult to replicate.
Key risk
Competitive datasets may emerge from larger pharma; regulatory/IP challenges in data licensing.
Why now
AI-driven drug discovery is accelerating and labs are willing to license specialized datasets.
Competitors
Tempus AI, Recursion Pharmaceuticals data licensing
About
Creating the largest patient-derived cancer single-cell dataset for licensing to pharmaceutical and AI companies. These datasets are unique as they screen the effects of various drugs and genetic medicines under the control of our DNA switches.
Founders · 2
Yash RathodFounder
CEO @ Origin | Computer Science @ UIUC, Computer Vision and Reinforcement Learning Research, First Prize 2022 OpenCV AI Research Competition.
Malhar BhideFounder
CTO @ Origin | Prev: Computer Science @ UIUC, ML Research @ Wadhwani AI, Automorphic (YC S23). Published disease modeling research done in high school in Nature Scientific Reports.
Related startups
CellTypeWinter 2026
The agentic drug company. We simulate human biology.
AI-Driven Drug DiscoveryActive
Strand AIWinter 2026
Multimodal foundation models to predict uncollected patient biology
Biodata Foundation Models for Clinical TrialsActive
